Key Events This Week
28 Sep: Bullish momentum confirmed with 6.32% gain to Rs.59.40
29 Sep: Technical indicators upgrade and strong volume support
01 Oct: New 52-week high at Rs.65.4 and all-time high at Rs.65.25
01 Oct: Week closes at Rs.61.84, up 10.69% for the week
28 September: Bullish Momentum Shift Drives 6.32% Gain
Shukra Pharmaceuticals began the week with a strong rally, closing at Rs.59.40, up 6.32% from the previous close of Rs.55.87. This surge came despite the Sensex falling 1.60% to 34,788.97, highlighting the stock’s relative strength. The volume was robust at 796,063 shares, signalling strong investor interest. Technical indicators such as the Moving Average Convergence Divergence (MACD) and Bollinger Bands confirmed a bullish momentum shift, with the stock nearing its 52-week high of Rs.65.26. This marked a significant recovery from its 52-week low of Rs.26.30, reflecting renewed confidence in the company’s growth prospects.
29 September: Technical Upgrade and Continued Gains
The bullish momentum continued on 29 September, with the stock rising 1.70% to close at Rs.60.41. Although the Sensex declined by 0.48% to 34,621.52, Shukra Pharmaceuticals maintained its upward trajectory. The technical outlook improved further with the stock’s mojo grade upgraded to Buy from Hold on 22 September, supported by strong weekly and monthly MACD and Bollinger Bands signals. Despite a bearish weekly Relative Strength Index (RSI), the overall trend was positive, supported by bullish daily moving averages and Dow Theory assessments. However, On-Balance Volume (OBV) remained bearish on the weekly chart, indicating cautious volume confirmation of the rally.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
30 September: Steady Advance Amid Market Weakness
On 30 September, Shukra Pharmaceuticals extended its gains by 2.70%, closing at Rs.62.04, while the Sensex slipped 0.17% to 34,564.37. The stock’s volume remained healthy at 771,798 shares. The sustained rally was supported by the stock trading above all key moving averages, reinforcing the bullish technical setup. The company’s strong fundamentals, including an annualised net sales growth of 41.81% and operating profit growth of 114.99%, underpinned investor confidence. Despite some mixed signals from the weekly RSI and monthly Know Sure Thing (KST) indicators, the overall momentum remained positive.
1 October: New 52-Week and All-Time Highs Mark Milestone
Shukra Pharmaceuticals reached a new 52-week high of Rs.65.40 on 1 October, marking a significant milestone in its growth trajectory. The stock closed at Rs.61.84, down slightly by 0.32% on the day, but still up 10.69% for the week. This all-time high was supported by strong quarterly financial results, including a 1,225.61% increase in operating profit for the quarter ending June 2026 and a 135.1% rise in profit after tax to Rs.12.96 crores. The company’s conservative debt-to-equity ratio of 0.05 times and robust return on equity of 42.7% further reinforced its financial strength. Despite the Sensex’s continued weakness, falling 0.99% to 34,221.41, Shukra Pharmaceuticals demonstrated resilience and outperformance within the Pharmaceuticals & Biotechnology sector.
Curious about Shukra Pharmaceuticals Ltd from ? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-28 | Rs.59.40 | +6.32% | 34,788.97 | -1.60% |
| 2026-09-29 | Rs.60.41 | +1.70% | 34,621.52 | -0.48% |
| 2026-09-30 | Rs.62.04 | +2.70% | 34,564.37 | -0.17% |
| 2026-10-01 | Rs.61.84 | -0.32% | 34,221.41 | -0.99% |
Key Takeaways
Strong Outperformance: Shukra Pharmaceuticals outpaced the Sensex by a wide margin, gaining 10.69% while the benchmark index declined 3.20% over the week. This highlights the stock’s resilience amid broader market weakness.
Technical Momentum: The stock’s rally was supported by bullish MACD and Bollinger Bands signals on weekly and monthly charts, alongside positive daily moving averages. The mojo grade upgrade to Buy further validated the technical strength.
Financial Robustness: Exceptional quarterly growth with a 1,225.61% increase in operating profit and strong net sales growth of 41.81% underpin the stock’s fundamental appeal. Conservative leverage and high return on equity reinforce financial stability.
Valuation Considerations: Despite premium valuation metrics such as a P/B ratio of 32.6 and a P/E ratio of 81 times trailing earnings, the PEG ratio of 0.3 suggests earnings growth justifies the price premium.
Volume and Momentum Caution: Some bearish signals from weekly RSI and On-Balance Volume indicate the need for cautious monitoring of volume confirmation to sustain the rally.
Conclusion
Shukra Pharmaceuticals Ltd’s 10.69% weekly gain, culminating in new 52-week and all-time highs, reflects a compelling combination of strong technical momentum and robust financial performance. The stock’s ability to outperform the Sensex during a weak market week underscores its distinctive position within the Pharmaceuticals & Biotechnology sector. While valuation remains elevated, the company’s exceptional earnings growth and conservative capital structure provide a solid foundation for its current market standing. Investors should remain attentive to volume trends and short-term momentum indicators to navigate potential volatility in this micro-cap stock’s ongoing rally.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
